These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 26775732)

  • 61. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
    Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.
    Smith JJ; Chatila WK; Sanchez-Vega F; Datta J; Connell LC; Szeglin BC; Basunia A; Boucher TM; Hauser H; Wasserman I; Wu C; Cercek A; Hechtman JF; Madden C; Jarnagin WR; Garcia-Aguilar J; D'Angelica MI; Yaeger R; Schultz N; Kemeny NE
    Cancer Med; 2019 Nov; 8(15):6538-6548. PubMed ID: 31503397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
    Jácome AA; Vreeland TJ; Johnson B; Kawaguchi Y; Wei SH; Nancy You Y; Vilar E; Vauthey JN; Eng C
    Br J Cancer; 2021 Feb; 124(4):797-804. PubMed ID: 33208919
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
    Mao C; Wu XY; Yang ZY; Threapleton DE; Yuan JQ; Yu YY; Tang JL
    Sci Rep; 2015 Feb; 5():8065. PubMed ID: 25639985
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.
    Koochak A; Rakhshani N; Karbalaie Niya MH; Tameshkel FS; Sohrabi MR; Babaee MR; Rezvani H; Bahar B; Imanzade F; Zamani F; Khonsari MR; Ajdarkosh H; Hemmasi G
    Asian Pac J Cancer Prev; 2016; 17(2):603-8. PubMed ID: 26925650
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
    O Connor JM; Sanchez Loria F; Ardiles V; Grondona J; Sanchez P; Andriani O; Fauda M; Brancato F; Huertas E; Alvarez F; de Santibañes E
    Future Oncol; 2019 Sep; 15(27):3149-3157. PubMed ID: 31426677
    [No Abstract]   [Full Text] [Related]  

  • 68. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 69. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.
    Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM
    Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.
    Margonis GA; Buettner S; Andreatos N; Wagner D; Sasaki K; Barbon C; Beer A; Kamphues C; Løes IM; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    Ann Surg; 2019 Jun; 269(6):1129-1137. PubMed ID: 31082912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
    Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
    PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
    [TBL] [Abstract][Full Text] [Related]  

  • 74. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis.
    Huang J; Zang Q; Wen Y; Pan Z; Yao Z; Huang M; Huang J; Chen J; Wang R
    Crit Rev Oncol Hematol; 2021 Apr; 160():103308. PubMed ID: 33753248
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
    Shoji H; Yamada Y; Taniguchi H; Nagashima K; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Cancer Sci; 2014 Aug; 105(8):1002-7. PubMed ID: 24863535
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
    [TBL] [Abstract][Full Text] [Related]  

  • 78. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.
    Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW
    Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388
    [TBL] [Abstract][Full Text] [Related]  

  • 79. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
    Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI
    Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
    Takeda Y; Mise Y; Takahashi Y; Ito H; Inoue Y; Yoshioka R; Ono Y; Saiura A
    Ann Surg Oncol; 2022 Apr; 29(4):2383-2391. PubMed ID: 34851437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.